Parkinsons Disease Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Parkinson's Disease Therapeutics Market and it is segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), and Geography (North America, Europe, Asia Pacific, Middle East, and Africa, and South America). The market provides the value (in USD million) for the above segments.

Parkinsons Disease Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Parkinson's Disease Drugs Market Size

Parkinson's Disease Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 5.76 Billion
Market Size (2030) USD 6.87 Billion
CAGR (2025 - 2030) 3.58 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Parkinson's Disease Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Parkinson's Disease Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Parkinson's Disease Drugs Market Analysis

The Global Parkinson's Disease Drugs Market size is estimated at USD 5.76 billion in 2025, and is expected to reach USD 6.87 billion by 2030, at a CAGR of 3.58% during the forecast period (2025-2030).

The Covid-19 pandemic has impacted the market significantly. The COVID-19 pandemic had few major effects on the global market for Parkinson's disease drugs market. The pandemic has directly affected the production and demand of parkinson's drugs; it has disrupted distribution channels, and it has had a financial impact on firms and financial markets. However, the clinical trials have increased, and numerous research has been conducted to find the impact of Covid-19 on PD patients. For instance, in the article 'Clinical Trials of Parkinson's Therapies Robust Despite COVID-19' published in August 2021 it is mentioned that despite the impact of COVID-19, investment and interest in clinical trials of potential new treatments for Parkinson's disease remained strong during the pandemic phase. Another research article was published in the same month titled 'Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update' and as per the article, there has been considerable activity in the clinical development of innovative and efficient drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD) during the pandemic. Therefore, owing to the mentioned factors, the pandemic is expected to have a positive impact on the market studied.

Factors such as the rising geriatric population and burden of Parkinson's disease, growing awareness among the population, increasing research and development, and continuous drug approvals are expected to fuel the market growth.

For instance, the global prevalence of Parkinson's disease is estimated to be approximately 6.1 million globally, and the prevalence increases with age, reaching 1% to 3% in the population over 65 years of age, as per the research article 'Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future' published in February 2022. In addition, the data updated by World Health Organization (WHO) in October 2021 shows that by 2030, 1 in 6 people in the world will be aged 60 years or over. Hence, the world is anticipated to witness a demographic shift with an increase in the geriatric population, globally. Owing to the increase of older adults, the prevalence and incidence of PD are expected to demand new therapeutics and drugs for treatment. Thereby, boosting the market growth over the analysis period.

Moreover, the recent developments and strategic activities by major or minor market players are increasing in both regional markets and global markets. This is another major factor anticipated to exponentially bolster the studied market. For instance, in December 2021, Israel-based Pharma Two B Ltd., declared its Phase III double-blind, active-controlled study of P2B001 in early Parkinson's disease successfully met its primary and key secondary endpoints in the Phase III study, P2B001 was superior to each of its individual components as measured by the change from baseline to week 12 in total Unified Parkinson's Disease Rating Scale. P2B001 was superior to the pramipexole component by 2.66 points (p=0.0018) and superior to the rasagiline component by 3.30 points (p=0.0001).

In addition, in January 2022, Iktos, a South Korea-based company specializing in artificial intelligence (AI) for novel drug design and Astrogen, a clinical and research-oriented biotech company focused on developing innovative new drugs for the treatment of intractable neurological diseases entered into a research collaboration agreement which is aimed at the discovery of innovative small molecule pre-clinical drug candidates for Parkinson's disease. Additionally, in March 2022, Vyant Bio, Inc. an innovative biotechnology company focused on reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders, and OrganoTherapeutics, a developer of proprietary patient-specific organoids that recapitulate Parkinson's Disease (PD) pathology, entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson's Disease. Therefore, the continuous advancements in the Parkinson's disease drug segment are anticipated to fuel the market growth over the analysis period.

Therefore, owing to the factors above, the market studied is expected to witness growth over the forecast period. However, high costs associated with the research and development of drugs and therapies lead to the high cost of drugs and this is predicted to hinder market growth slightly.

Parkinson's Disease Drugs Industry Overview

The Parkinson's disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of the global pharmaceutical firms are contributing to the dynamic nature of the market. Several new products are expected to be launched during the forecast period, which may lead to significant changes in the market shares of pharmaceutical firms that are currently active in the market. Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Pfizer Inc., and Novartis AG are some of the major players among others.drug

Parkinson's Disease Drugs Market Leaders

  1. GlaxoSmithKline PLC

  2. Boehringer Ingelheim International GmbH

  3. Newron Pharmaceuticals SPA

  4. F. Hoffmann-La Roche Ltd

  5. AbbVie Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Parkinson's Disease Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Parkinson's Disease Drugs Market News

  • In March 2022, Neuron23 raised USD 100 million to advance Parkinson's disease therapy. The company intends to commence the trials of NEU-723 to potentially treat Parkinson's disease by the end of this year.
  • In January 2022, Clinical-stage biotech company ABL Bio Inc. collaborated and entered into a worldwide license agreement with Sanofi to develop and commercialize a treatment for Parkinson's disease and other potential indications. The treatment, ABL301, is a preclinical stage bispecific antibody that targets alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) with bolstered penetration of the blood-brain barrier.

Parkinson's Disease Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population and Burden of Parkinson's Disease
    • 4.2.2 Growing Awareness Among the Population
    • 4.2.3 Increasing R&D and Continuous Drug Approvals
  • 4.3 Market Restraints
    • 4.3.1 Adverse Events Associated with Therapeutics
    • 4.3.2 High Cost of Treatments Followed by Extremely High R&D Expenditure
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD Million)

  • 5.1 By Mechanism of Action
    • 5.1.1 Dopamine Agonists
    • 5.1.2 Anticholinergic
    • 5.1.3 MAO-B inhibitors
    • 5.1.4 Amantadine
    • 5.1.5 Carbidopa-levodopa
    • 5.1.6 COMT Inhibitors
    • 5.1.7 Other Mechanisms of Action
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amneal Pharmaceuticals LLC
    • 6.1.2 AbbVie Inc.
    • 6.1.3 Viatris
    • 6.1.4 Boehringer Ingelheim International GmbH
    • 6.1.5 GSK plc
    • 6.1.6 ABL bio
    • 6.1.7 Teva Pharmaceuticals Industries Ltd
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 F. Hoffmann-La Roche Ltd
    • 6.1.11 Kissei Pharmaceutical Co., Ltd.
    • 6.1.12 AstraZeneca
    • 6.1.13 Prevail Therapeutics
    • 6.1.14 Newron Pharmaceuticals SPA
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Parkinson's Disease Drugs Industry Segmentation

As per the scope, parkinson's disease is a brain condition that results in unintentional or uncontrollable movements like trembling, stiffness, and issues with balance and coordination. The Parkinson's disease drugs market is segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), and GeographyGeography (North America, Europe, Asia Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Mechanism of Action Dopamine Agonists
Anticholinergic
MAO-B inhibitors
Amantadine
Carbidopa-levodopa
COMT Inhibitors
Other Mechanisms of Action
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Parkinson's Disease Drugs Market Research FAQs

How big is the Global Parkinson's Disease Drugs Market?

The Global Parkinson's Disease Drugs Market size is expected to reach USD 5.76 billion in 2025 and grow at a CAGR of 3.58% to reach USD 6.87 billion by 2030.

What is the current Global Parkinson's Disease Drugs Market size?

In 2025, the Global Parkinson's Disease Drugs Market size is expected to reach USD 5.76 billion.

Who are the key players in Global Parkinson's Disease Drugs Market?

GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd and AbbVie Inc. are the major companies operating in the Global Parkinson's Disease Drugs Market.

Which is the fastest growing region in Global Parkinson's Disease Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Parkinson's Disease Drugs Market?

In 2025, the North America accounts for the largest market share in Global Parkinson's Disease Drugs Market.

What years does this Global Parkinson's Disease Drugs Market cover, and what was the market size in 2024?

In 2024, the Global Parkinson's Disease Drugs Market size was estimated at USD 5.55 billion. The report covers the Global Parkinson's Disease Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Parkinson's Disease Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Parkinson's Disease Drugs Industry Report

The Parkinson's Disease Therapeutics Market report covers various segments based on the mechanism of action, including dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action. The geographical segmentation includes North America, Europe, Asia Pacific, the Middle East and Africa, and South America. This market analysis provides valuable insights into the market size and market share, along with a detailed market forecast and market trends.

The industry analysis highlights the significant growth rate in the Parkinson's Disease Drugs market, supported by comprehensive industry research and market data. The industry overview and market review offer a historical perspective, while the market outlook and market predictions give a forward-looking view up to the forecast period.

The report includes in-depth industry information and industry statistics, offering a clear picture of the market segmentation and market value. It also identifies market leaders and their contributions to market growth. The industry reports and market report are essential tools for understanding the overall market dynamics.

For those interested in further details, the report example and report PDF are available for download. These documents provide a thorough examination of the market, supported by industry sales and market research from leading research companies. The industry trends and market overview sections offer insights into the evolving landscape of Parkinson's Disease Therapeutics, ensuring stakeholders are well-informed about current and future market conditions.